Review: taking Coumadin and Phenytoin together


Summary

Drug interactions are reported among people who take Coumadin and Phenytoin together. This review analyzes the effectiveness and drug interactions between Coumadin and Phenytoin. It is created by eHealthMe based on reports of 1,571 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Coumadin and Phenytoin >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Coumadin

Coumadin has active ingredients of warfarin. It is often used in atrial fibrillation/flutter. (latest outcomes from Coumadin 73,270 users)

Phenytoin

Phenytoin has active ingredients of phenytoin. It is often used in convulsion. (latest outcomes from Phenytoin 14,546 users)

On Jul, 20, 2016

1,571 people who take Coumadin, Phenytoin are studied.


Number of reports submitted per year:

Coumadin and Phenytoin drug interactions.

Drug effectiveness over time:

Coumadin:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 62.0% - (5 of 8 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (2 of 2 people)
  • 2 - 5 years: 85.0% - (6 of 7 people)
  • 5 - 10 years: 50.0% - (1 of 2 people)
  • 10+ years: 100.0% - (2 of 2 people)
  • not specified: 0.0% - (0 of 0 people)
Phenytoin:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 100.0% - (3 of 3 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 75.0% - (9 of 12 people)
  • not specified: 100.0% - (2 of 2 people)

Drug effectiveness by gender:

Coumadin:
  • female: 83.0% - (10 of 12 people)
  • male: 66.0% - (6 of 9 people)
Phenytoin:
  • female: 83.0% - (10 of 12 people)
  • male: 80.0% - (8 of 10 people)

Drug effectiveness by age:

Coumadin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 42.0% - (3 of 7 people)
  • 50-59: 100.0% - (9 of 9 people)
  • 60+: 75.0% - (3 of 4 people)
Phenytoin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 71.0% - (5 of 7 people)
  • 50-59: 88.0% - (8 of 9 people)
  • 60+: 80.0% - (4 of 5 people)

Most common drug interactions over time *:

< 1 month:
  • international normalised ratio increased
  • alanine aminotransferase increased
  • convulsion
  • transaminases increased
  • hereditary angioedema
  • pancreatitis
  • pancytopenia
  • urinary tract infection
  • status epilepticus
  • stevens-johnson syndrome
1 - 6 months:
  • international normalised ratio increased
  • cardiomegaly
  • coma hepatic
  • convulsion
  • delirium
  • hepatic failure
  • hepatorenal syndrome
  • hyperthyroidism
  • blindness unilateral
  • dyspnoea
6 - 12 months:
  • brain herniation
  • cholecystitis acute
  • cholelithiasis
  • drug level increased
  • fall
  • speech disorder
  • subdural haematoma
  • death
  • haemorrhage intracranial
  • haemorrhagic stroke
1 - 2 years:
  • fall
  • syncope
  • atrophy
  • blood viscosity increased
  • dizziness (excl vertigo)
  • insomnia
  • laceration
  • lethargy
  • nervousness
  • stress symptoms
2 - 5 years:
  • aphasia
  • cerebral artery embolism
  • cerebral haemorrhage
  • confusional state
  • convulsion
  • fall
  • haemorrhagic stroke
  • headache
  • insomnia
  • akathisia
5 - 10 years:
  • anticonvulsant drug level decreased
  • convulsion
  • international normalised ratio increased
  • abdominal distension
  • abdominal pain lower
  • aphasia
  • bladder disorder
  • cardiac disorder
  • cardio-respiratory arrest
  • chest pain
10+ years:
  • arthritis
  • hot flushes
  • lupus-like syndrome
  • night sweats
  • aphagia
  • blood cholesterol increased
  • c-reactive protein increased
  • cardiac fibrillation
  • coma
  • drug ineffective
not specified:
  • convulsion
  • pain
  • international normalised ratio increased
  • fall
  • asthenia
  • dyspnoea
  • headache
  • anxiety
  • oedema peripheral
  • dizziness

Most common drug interactions by gender *:

female:
  • pain
  • headache
  • asthenia
  • convulsion
  • depression
  • international normalised ratio increased
  • anxiety
  • bone disorder
  • fatigue
  • pain in extremity
male:
  • convulsion
  • international normalised ratio increased
  • fall
  • pain
  • renal failure
  • oedema peripheral
  • dyspnoea
  • confusional state
  • deep vein thrombosis
  • hypotension

Most common drug interactions by age *:

0-1:
  • sedation
  • weakness
2-9:
  • mucosal haemorrhage
  • thrombocytopenia
  • anxiety
  • death
  • depression
  • fear
  • injury
  • multi-organ failure
  • pain
  • renal failure
10-19:
  • international normalised ratio increased
  • stevens-johnson syndrome
  • alopecia
  • convulsion
  • haematemesis
  • leg traumatic amputation
  • phantom limb pain
  • status epilepticus
  • superior sagittal sinus thrombosis
  • thalamic infarction
20-29:
  • nephrogenic systemic fibrosis
  • pain
  • mobility decreased
  • peroneal nerve palsy
  • skin depigmentation
  • skin tightness
  • dry skin
  • extremity contracture
  • hyperkeratosis
  • oedema
30-39:
  • oedema peripheral
  • pain
  • joint contracture
  • joint range of motion decreased
  • nephrogenic systemic fibrosis
  • skin hypertrophy
  • skin tightness
  • pruritus
  • anxiety
  • myocardial infarction
40-49:
  • deep vein thrombosis
  • confusional state
  • urinary tract infection
  • convulsion
  • cytokine storm
  • delirium
  • anaemia
  • body temperature increased
  • impetigo
  • petechiae
50-59:
  • pain
  • international normalised ratio increased
  • arthralgia
  • anxiety
  • fall
  • convulsion
  • bronchitis
  • oedema peripheral
  • chronic obstructive pulmonary disease
  • back pain
60+:
  • convulsion
  • international normalised ratio increased
  • fall
  • pain
  • depression
  • asthenia
  • atrial fibrillation
  • dyspnoea
  • headache
  • dizziness

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Coumadin and Phenytoin?

Can you answer these questions?

More questions for: Coumadin, Phenytoin

You may be interested in these reviews

More reviews for: Coumadin, Phenytoin

On eHealthMe, Coumadin (warfarin) is often used to treat atrial fibrillation/flutter. Phenytoin (phenytoin) is often used to treat convulsion. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.